A behind-the-scenes look at the most lucrative discipline within biotechnology Bioinformatics represents a new area of opportunity for investors and industry participants. Companies are spending billions on the potentially lucrative products that will come from bioinformatics. This book looks at what companies like Merck, Glaxo SmithKline Beecham, and Celera, and hospitals are doing to maneuver themselves to leadership positions in this area. Filled with in-depth insights and surprising...
